Related Experiment Video
Updated: May 5, 2026

23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
7.5K
[Taro Okamoto and Parkinson's Disease]
1Department of General Internal Medicine, National Center of Neurology and Psychiatry (NCNP) National Center Hospital.
Brain and Nerve = Shinkei Kenkyu No Shinpo
|December 5, 2024
Summary
This study explores how anti-Parkinson drugs influenced artist Taro Okamoto's creativity amidst his Parkinson's disease. It examines changes in his artistic focus and discusses the cause of his death.
Area of Science:
- Art History
- Neurology
- Medical Humanities
Background:
- Parkinson's disease (PD) affects motor and non-motor functions, impacting individuals globally.
- Famous Japanese artist Taro Okamoto developed PD later in life, experiencing facial pareidolia.
- PD-related visual impairments, including color vision deficits and reduced contrast sensitivity, influenced Okamoto's artistic output.
Purpose of the Study:
- To investigate the impact of anti-Parkinson drugs on Taro Okamoto's creative process.
- To analyze the shift in his artistic medium from painting to ceramics and sculpture.
- To discuss the etiology of acute respiratory failure leading to his death.
Main Methods:
- Qualitative analysis of Okamoto's artistic works and personal records.
- Review of medical literature on Parkinson's disease and its effects on creativity.
- Examination of the pharmacological effects of anti-Parkinson medications.
Main Results:
- Anti-Parkinson drugs may have modulated Okamoto's perception and creative expression.
- The study correlates changes in his visual perception with his artistic medium transition.
- Facial pareidolia influenced his "Glass with Face" concept.
Conclusions:
- Anti-Parkinson medications potentially influenced Okamoto's artistic trajectory.
- Understanding the interplay between neurological disease, medication, and creativity offers insights into artistic adaptation.
- The study highlights the complex relationship between neurological conditions and artistic output.
Related Concept Videos
Parkinson's Disease: Overview
479
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
479
Parkinson's Disease: Treatment
219
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
219
Alzheimer's Disease: Overview
447
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
447
Alzheimer's Disease: Treatment
163
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
163
Narcolepsy
89
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
89
Panic Disorder
38
Panic disorder is an anxiety disorder characterized by recurrent and sudden minutes-long episodes of intense fear, known as panic attacks. These attacks may feel like heart attacks and often happen without warning or a specific cause. They can include symptoms such as rapid heart rate, shortness of breath, chest pain, trembling, sweating, dizziness, and a sense of helplessness. During a panic attack, individuals may feel as though they are experiencing a heart attack or are in a...
38

